Treace Medical Concepts Q2 2025 Earnings Report

Treace Medical Concepts EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.28
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Treace Medical Concepts Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $47.08 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Treace Medical Concepts Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 5, 2025
• Conference Call Time: 4:30PM ET

Treace Medical Concepts (NASDAQ:TMCI) is a medical device company focused on the design, development and commercialization of innovative solutions for foot and ankle disorders. The company’s flagship offering is its Lapiplasty 3D Bunion Correction system, which is engineered to address the root cause of bunions by correcting deformities in all three planes of motion. Treace’s portfolio also includes proprietary instruments, implants and fixation systems designed to simplify surgical workflows and improve patient outcomes.

Treace markets its products through a direct sales force that educates surgeons on the clinical and biomechanical benefits of its technologies. The company provides hands-on training, procedural support and ongoing clinical research to validate its approach. In addition to bunion correction, Treace is developing next-generation implants for related foot and ankle procedures, leveraging its platform of patented designs and materials expertise.

Founded in 2013 by Chris Roche and David P. Petty, Treace has rapidly expanded its intellectual property portfolio and secured FDA clearance for its Lapiplasty system in 2015. Under the leadership of Chief Executive Officer Chris Roche and Chief Medical Officer Dr. Mark Gillette, the company has built a dedicated team of engineers, surgeons and sales professionals committed to advancing the standard of care in foot and ankle surgery.

Headquartered in Ponte Vedra Beach, Florida, Treace serves orthopaedic surgeons and podiatrists across the United States, with plans to expand into key international markets. By collaborating with leading clinical investigators and participating in major industry conferences, the company aims to broaden the adoption of its solutions and support long-term improvements in patient mobility and quality of life.